Dapagliflozin, a SGLT2 inhibitor and sirtinol, a SIRT1 inhibitor, were used to investigate the role of the SGLT2-SIRT1 pathway in AF in a streptozotocin (STZ)-induced diabetes mellitus [121]. The gene discussed is SIRT1; the disease is diabetes mellitus.